{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:33:22Z","timestamp":1791117202216,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,8,23]],"date-time":"2006-08-23T00:00:00Z","timestamp":1156291200000},"content-version":"vor","delay-in-days":53,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wound Repair Regeneration"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Apligraf<jats:sup>\u00ae<\/jats:sup> is a bilayered tissue\u2010engineered product consisting of a bovine collagen matrix with neonatal fibroblasts, overlaid by a stratified epithelium containing living keratinocytes. The United States Food and Drug Administration has approved its use for venous leg ulcers and neuropathic diabetic foot ulcers. Apligraf<jats:sup>\u00ae<\/jats:sup> provides a dermal matrix and produces cytokines similar to the human skin. However, its mechanism of action and ultimate fate in host wounds are unclear. The aim of this study was to evaluate the persistence of Apligraf<jats:sup>\u00ae<\/jats:sup> fibroblasts and keratinocytes in human acute partial\u2010thickness wounds (split\u2010thickness donor sites) treated with Apligraf<jats:sup>\u00ae<\/jats:sup>. In an open\u2010label, within\u2010patient, three\u2010centered, controlled pilot study, 10 patients were treated with Apligraf<jats:sup>\u00ae<\/jats:sup>, Apligraf<jats:sup>\u00ae<\/jats:sup> dermis only (without epidermis), and a polyurethane film for donor site wounds of the same size, depth, and anatomical location. Apligraf<jats:sup>\u00ae<\/jats:sup> DNA persistence was the primary outcome measure. Basement membrane components, cosmetic outcome, time to wound healing, and safety parameters were secondary outcome measures. One week after the initial treatment, reverse transcription polymerase chain reaction analysis found that two Apligraf<jats:sup>\u00ae<\/jats:sup> and two Apligraf<jats:sup>\u00ae<\/jats:sup> dermis\u2010only\u2010treated sites had Apligraf<jats:sup>\u00ae<\/jats:sup> DNA present. Four weeks posttreatment, only one Apligraf<jats:sup>\u00ae<\/jats:sup> and one Apligraf<jats:sup>\u00ae<\/jats:sup> dermis\u2010only sites showed the presence of Apligraf<jats:sup>\u00ae<\/jats:sup> DNA. There was no difference between the three treatment modalities in establishing basement membrane in donor site wounds. No differences in other secondary outcomes were found. Apligraf<jats:sup>\u00ae<\/jats:sup> DNA persisted in a minority of patients at 4 weeks in acute partial\u2010thickness wounds. Apligraf<jats:sup>\u00ae<\/jats:sup>'s success in speeding healing of acute wounds appears to be related to factors other than the persistence of donor DNA or effect on basement membrane restoration.<\/jats:p>","DOI":"10.1111\/j.1743-6109.2006.00148.x","type":"journal-article","created":{"date-parts":[[2006,8,23]],"date-time":"2006-08-23T15:40:54Z","timestamp":1156347654000},"page":"427-433","source":"Crossref","is-referenced-by-count":83,"title":["Evaluation of Apligraf<sup>\u00ae<\/sup> persistence and basement membrane restoration in donor site wounds: a pilot study"],"prefix":"10.1111","volume":"14","author":[{"given":"Shasa","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Eaglstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,8,23]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"915","article-title":"Healing of venous ulcers of long duration with a bilayered living skin substitute","volume":"27","author":"Brem H","year":"2001","journal-title":"results from a general surgery and dermatology department"},{"key":"e_1_2_6_3_2","first-page":"627","article-title":"Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent","volume":"135","author":"Brem H","year":"2000","journal-title":"a new paradigm in wound healing"},{"key":"e_1_2_6_4_2","first-page":"673","article-title":"Novel treatment strategy for leg and sternal wound complications after coronary artery bypass graft surgery","volume":"78","author":"Allie DE","year":"2004","journal-title":"bioengineered Apligraf"},{"key":"e_1_2_6_5_2","first-page":"913","article-title":"Behavior of tissue\u2010engineered skin","volume":"135","author":"Muhart M","year":"1999","journal-title":"a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(00)00017-6"},{"key":"e_1_2_6_7_2","first-page":"284","article-title":"Epidermolysis bullosa","volume":"16","author":"Trent JT","year":"2003","journal-title":"identification and treatment"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.502"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.8.1079"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1993.tb00424.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1993.tb01991.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.3.293"},{"key":"e_1_2_6_13_2","first-page":"290","article-title":"Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers","volume":"24","author":"Veves A","year":"2001","journal-title":"a prospective randomized multicenter clinical trial"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.10.1225"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-93-3-240"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.107962"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01763.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2000.026010946.x"},{"key":"e_1_2_6_19_2","first-page":"311","article-title":"Cultured skin as a \u2018smart material\u2019 for healing wounds","volume":"17","author":"Sabolinski ML","year":"1996","journal-title":"experience in venous ulcers"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199301000-00024"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199906270-00014"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1995.tb00709.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.1999.08186.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.2004.10.1180"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1989.01670180069008"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6678.917"},{"key":"e_1_2_6_27_2","first-page":"524","article-title":"Human chronic wounds treated with bioengineered skin","volume":"46","author":"Badiavas EV","year":"2002","journal-title":"histologic evidence of host-graft interactions"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70160-2"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb08243.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archderm.1993.01680250093014","article-title":"The biology of skin grafts. Skin grafts as pharmacologic agents","volume":"129","author":"Kirsner RS","year":"1993","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04563.x"},{"key":"e_1_2_6_32_2","first-page":"653","article-title":"Wounding of bioengineered skin","volume":"119","author":"Falanga V","year":"2002","journal-title":"cellular and molecular aspects after injury"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90140-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12329920"}],"container-title":["Wound Repair and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-6109.2006.00148.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-6109.2006.00148.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:00:50Z","timestamp":1697266850000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-6109.2006.00148.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1743-6109.2006.00148.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00148.x","archive":["Portico"],"relation":{},"ISSN":["1067-1927","1524-475X"],"issn-type":[{"value":"1067-1927","type":"print"},{"value":"1524-475X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}